May 3, 2023
VIA EDGAR SUBMISSION
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, DC 20549
Attention: Arzhang Navai
| Re: | Karyopharm Therapeutics Inc. |
Registration Statement on Form S-3
File No. 333-269846
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Karyopharm Therapeutics Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-269846), so that it may become effective at 4:30 p.m., Eastern Time, on May 5, 2023, or as soon as practicable thereafter, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff.
| Very truly yours, | ||
| /s/ KARYOPHARM THERAPEUTICS INC. | ||
| By: | /s/ Michael Mano | |
| Name: Michael Mano | ||
| Title: Senior Vice President and General Counsel | ||
| cc: | Jason Kropp, Wilmer Cutler Pickering Hale and Dorr LLP |
Craig Hilts, Wilmer Cutler Pickering Hale and Dorr LLP